The fourth batch of National Novarce, Yang Sen and other quotations over the limit price! 90% drop in multiple injections

On February 3, 2021, the fourth batch of State Harvest was officially opened in Shanghai.
news that the results of the proposed election have been produced.
this centralized procurement of a total of 158 selected products.
52 per cent, with a maximum drop of 96 per cent.
estimates, the fourth batch of drug collection is expected to save 12.4 billion yuan a year.
this collection into a total of 45 varieties of 80 product rules, the highest procurement scale of more than 25 billion yuan, involving more than 120 pharmaceutical companies.
involved in pharmaceutical companies, the largest number of domestic reviews are Qilu, Yangzijiang, Shi Pharmaceutical Group, multinational pharmaceutical companies involved in the largest number of products are Novart, Bronger Ingham, AstraZenecon.
The fourth batch of national harvest site photo / shoals this collection of varieties covering diabetes, hypertension, respiratory diseases, psychotherapy, tumor drugs, fungal infections, anaesthetic pain, eye drops and other drug areas, 45 varieties of 8 injection varieties, 3 eye drops, the others are oral dosage forms.
45 products include 7 national Medicare Class A drugs, 35 Class B drugs, and 2 uninsured drugs (ibuprofen injections, injections of bivaldes).
compared to the first three batches, the number of finalists in this round expanded again, the maximum number of finalists reached 10 (the finalist rules specifically 1 into 1/2 into 2, 3 into 2, 4 into 3, 5 into 4, 6 into 4, 7 into 5, 8 into 6, 9 into 7, 10 into 8, 11 into 9, 12 into 9, ≥13 into 10).
the entry rule is still three sufficient conditions: 1. the quotation is not higher than 1.8 times the minimum price;
this morning, some of the bidding on the spot flowed out, we combed the information.
(Note: The results are based on official publication and are for informational purposes only.)
) The fierce competition for injections of parexib sodium decreased by nearly 95%, it is noteworthy that a total of 8 injection varieties were selected in this round, namely, ammonia bromine injections, propofol medium long-chain fat milk, ibuprofen injections, doso-tea-alkali injections, Paresib injections, fentanyl injections, boratezomi injections and injections with bivaldiol.
Nomura Oriental International Securities pointed out that these are clinical large varieties, 8 products in 2019 sample hospital revenue accounted for 45 varieties in 2019 total sample hospital revenue of more than 30%.
the inclusion of large varieties of injectables in the national market or will directly affect the sales revenue of dozens of pharmaceutical companies.
other varieties of local procurement cycle, there are also special requirements for 8 injection products, the current procurement cycle clearly stated in principle for 1 year.
different from chemical drugs, the hospital market is the main "battleground" of injection products, whether the winning bid for enterprises is a matter of life and death.
is also noteworthy, with the largest sales of vitolazole injections.
meters intranet data show that the drug in 2019 in the domestic public hospital terminal sales reached 6,669 million yuan, the original research drug company Takeda Pharmaceuticals has 11.7% of the market share, Yangzijiang accounted for 28%.
the current evaluation of enterprises only Meihua East, Yangzijiang Pharmaceuticals, Osaikang.
, according to local media reports, the anti-latola injection bidding enterprises are Takeda, Yangzijiang, Jiangsu Osaikang, Nanjing Zhengda Tianqing, Central and Eastern China and other enterprises.
40mg injection of lutonazine in Yangzijiang was quoted at 23.4, with a price of 3.9 yuan per tablet, a decrease of 86.3%.
East China Pharmaceutical Subsidiary, China East China, Four Rings Pharmaceuticals and other anti-torazole injections have been announced has been successfully bid.
bid, the two injections, Ambluroso and Parexib, are the most competitive, with more than 10 companies competing with each other.
ammonia bromoso injections involving enterprises including Luoxin Pharmaceuticals, Colum Pharmaceuticals, Pate Pharmaceuticals, Shijiazhuang four drugs, etc. , Parexib injections involving enterprises including Qilu Pharmaceuticals, Hunan Colum, Wandong Bio, Haizheng Pharmaceuticals, Osaikang and so on.
In 2019, China's public hospitals have sales of ammonia bromoso injection terminals reached 5.98 billion yuan, the current market share of ammonia bromoso injections, Bringer Ingeham accounted for 23.56 percent of the market share;
on-site bidding situation, injection with Parexib sodium 20mg, Nanjing Zhengda Tianqing quoted 4.49 yuan, a drop of 91.9%.
40mg for injections: Pfizer offered 88.39 yuan, down just 5.9 percent, and Hunan Colum offered 56.4 yuan, down 94.0 percent.
also propofol medium long chain fat milk enterprise quotation has also been announced, a total of 5 enterprises to participate, the original research Feisen Yuscabi bid as low as 9.9 yuan, a drop of 85%.
, Jiangsu Yingke and Yangzijiang all won the bid, with bids of 14.86, 13.4 and 12.5, respectively, a decrease of 77%, 79% and 81%, respectively.
the four companies were to be selected, while Germany's Belang Medical offered a maximum of 15.5 out.
more than 50% reduction in the price of domestic sugar-lowering drugs The overall decline in the original research drugs is not only the "regular customer" of the medical insurance negotiations, but also the frequent visitors with volume procurement.
according to Sina Pharmaceuticals, the fourth batch of national mining included five sugar-lowering drugs, respectively, Engele net, Kagle net, Reglinay, Naglinai, Grezit.
and Kagele net belong to SGLT-2 inhibitors.
Among them, Engele Net has Hausen Pharmaceuticals and Colum Pharmaceuticals, Zhengda Tianqing 3 generic drugs were approved, Kagle Net's main review companies also include Haussen Pharmaceuticals and Zhengda Tianqing.
In addition to SGLT-2 inhibitors, the Glizit re-release tablets included in the collection are insulin-promoting drugs of sulfonylurea, and there are two non-sulfonate insulin-promoting agents, Reglinay and Naglinai.
specifically, Grezit, Naglinai and Reglinay were originally researched by Schweinstinger, Beijing Novart, Noor and Nord.
involved in the domestic generic pharmaceutical enterprises are Beijing Fuyuan, Yichang People's Fu, Zhuhai Tongyi, Jiangsu Haussen and so on.
To the first three batches of national sugar-lowering drugs - metformin hydrochloride, acapospose, gremezi tablets and other declines, the industry expects the current round of sugar-lowering drugs price reduction is still not small.
on-site quotations, a number of domestic sugar-lowering drugs fell by about half.
of these, engli net 10mg, the original research Bronger Ingelheim fell 24%, Colum, Howson, Zhengda Tianqing, Wanbang bio-bio-generics fell 53.1%, 52.8%, 50.5%, 49.9%, respectively.
the decline in domestic generics has conversed.
Kagle net 100mg, the original study of Yang Sen's single-piece price of 4.4369 yuan, higher than the limit price;
Gretzett, the original research Schweija single-chip price is higher than the limit price, Fuyuan, Renfu, Junan's three generic drugs fell 51., 37.0%, 5.3%, Price limits, Zhuhai Tongyi and Jiangsu Deyuan's two domestic generic drugs fell by 2.1% and 5.2%, respectively;
MNC offer: Novarce prudent Bayer, Sanders was sent out of the bureau in the national collection, domestic generic drug companies for the main bidding force, multinational pharmaceutical companies are relatively less active.
especially in the third batch of national mining, multinational pharmaceutical companies in order to maintain the global drug price system did not significantly reduce prices, many of the original research varieties because the bid is too high (above the limit) and early exit.
situation is similar in the fourth batch of state-owned enterprises.
In addition to the injections and diabetes products mentioned above, in the lung cancer target drug Sorafini, the original study of Bayer's Solafini (commodity name: Dojime) quoted 5388 yuan (60 tablets), the conversion price of 90 yuan per tablet, due to limited decline out.
the winning bid is suspected to be Jiangxi Shanxiang and Fosun Pharmaceutical subsidiary Chongqing Pharmaceutical Friends two domestic generic pharmaceutical companies.
injection than the four bidding enterprises, three domestic generic drugs won the bid, respectively, Hainan Puli Pharmaceuticals, Qilu Pharmaceuticals, Hainan Shuangcheng, the original research Sandes was sent out of the Bureau.
also observed, involving the largest varieties of Novaral, many varieties of quotations fell cautiously, the industry said its "heavy on participation" mentality is obvious.
the first batch of "4 plus 7" 25 varieties fell by an average of 56%, "4 plus 7" national expansion procurement decreased by 26%;
, the industry expects the average decline in the current round of national mining will also be more than 50%, for now, basically in line.
January 29, the State New Office held a policy briefing, the meeting has revealed the fourth batch of specific landing time, it is expected that in May this year patients can use the winning varieties.